WallStSmart

Insmed Inc (INSM)vsYD Bio Ltd (YDES)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 118723% more annual revenue ($606.42M vs $510,360). INSM leads profitability with a -2.1% profit margin vs -2.8%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

YDES

Avoid

22

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

YDES2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
95.6%10/10

Revenue surging 95.6% year-over-year

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

YDES4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$457.68M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-42.7%2/10

ROE of -42.7% — below average capital efficiency

Free Cash FlowQuality
$-298,1902/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : YDES

The strongest argument for YDES centers on Revenue Growth, Price/Book. Revenue growth of 95.6% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : YDES

The primary concerns for YDES are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while YDES is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

YDES is growing revenue faster at 95.6% — sustainability is the question.

YDES generates stronger free cash flow (-298,190), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

YD Bio Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.

Want to dig deeper into these stocks?